<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01320072</url>
  </required_header>
  <id_info>
    <org_study_id>10-01-002</org_study_id>
    <nct_id>NCT01320072</nct_id>
  </id_info>
  <brief_title>Diagnosis of Aspirin Hypersensitivity in Aspirin Exacerbated Respiratory Disease</brief_title>
  <acronym>ASAS</acronym>
  <official_title>Diagnosis of Aspirin Hypersensitivity in Aspirin Exacerbated Respiratory Disease Using a Safe, Low Dose Aspirin Challenge</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To diagnose aspirin hypersensitivity in asthmatics by using and safe, low-dose aspirin oral
      challenge.

      Hypothesis 1: A low dose of oral ASA (20 or 40 mg) will induce significantly different
      concentrations of arachidonic acid metabolites in ASA-sensitive asthmatics as compared to
      ASA-tolerant asthmatics.

      Hypothesis 2: The low dose (20 or 40 mg) ASA challenge will be well tolerated by
      ASA-sensitive asthmatics.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This research study is being conducted within the established Airway Research Group at
      Montefiore Medical Center and Albert Einstein College of Medicine in Bronx, NY. The patient
      population in the Bronx has one of the highest asthma prevalences in the country. Thus, our
      study participants are being recruited among the population most in need of a better
      understanding of the disease process.

      Visits 1 and 2: Low-dose challenge with 20 mg and 40 mg of ASA. ASA will be administered
      orally to participants in both groups: 20 mg at Visit 1 and 40 mg at Visit 2. Visits will
      take place at least 1 week apart. Blood and urine will be collected at several time points.

      Visit 3: Oral graded ASA challenge will be performed to confirm or rule out the presence of
      ASA-hypersensitivity. This visit will take place at least 1 week after Visit 2. Both groups
      will undergo an oral graded ASA challenge as per earlier described protocol. Urine and plasma
      will be collected from the patients at several time points. Hypersensitivity reactions will
      be defined in four different ways: a) decline in forced expiratory volume in 1 second (FEV1)
      of at least 15% combined and naso-ocular reaction; b) 20% decline in FEV1; c) isolated
      naso-ocular reactions; d) isolated cutaneous reactions (hives and swelling). Patients with
      reactions will be treated according to their symptoms.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Eicosanoid Metabolites Concentration</measure>
    <time_frame>2 hours</time_frame>
    <description>eicosanoid metabolites concentration in plasma and urine 2 h post ASA challenge</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment-Related Adverse Events</measure>
    <time_frame>24 hours after the challenge</time_frame>
    <description>Adverse reactions defined as bronchospasm requiring endotracheal intubation. The adverse reactions will be assessed through a post challenge follow-up with the patient at baseline and 24 hours after the challenge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Forced Expiratory Volume in One Second (FEV1) in Aspirin Exacerbated Respiratory Disease (AERD) Patients</measure>
    <time_frame>12 months</time_frame>
    <description>We will assess FEV1% change from baseline at 12 months in AERD patients who have been on aspirin treatment for 12 months (current standard of care)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">29</enrollment>
  <condition>Asthma, Aspirin-induced</condition>
  <arm_group>
    <arm_group_label>Aspirin-sensitive asthmatics</arm_group_label>
    <description>asthma patients with aspirin allergy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>aspirin-tolerant asthmatics</arm_group_label>
    <description>asthma patients without aspirin allergy</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      urine, peripheral blood mononuclear cells, plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Allergy/Immunology clinic population in Bronx, NY
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Participants of both sexes aged 18 years and older.

          2. Patients with a history of ASA-induced asthma who had at least one asthma attack after
             ingestion of aspirin or other NSAIDs.

          3. Patients with a history of ASA-tolerant asthma who had been occasionally using aspirin
             or other NSAIDs without any adverse reactions.

        Exclusion Criteria:

          1. Mental or legal incapacitation, or significant emotional problems, or a history of
             psychiatric disorders at the time of the enrollment.

          2. Pregnancy or breastfeeding at the time of enrollment.

          3. History of a severe anaphylactic reaction precipitated by ASA and/or other NSAIDs
             (such as ibuprofen, naproxen, indomethacin, Advil, Aleve, Motrin, diclofenac, etc.).

          4. History of a severe bronchospasm precipitated by ASA and/or other NSAIDs requiring an
             endotracheal intubation.

          5. Chronic kidney disease (a calculated GFR based on the Modification of Diet in Renal
             Disease (MDRD) equation is &lt; 60 mL/min/1.73 sq.meter).

          6. Chronic liver disease by history and/or abnormal liver function tests (SGOT and SGPT â‰¥
             3 times above upper normal range).

          7. Baseline FEV1 &lt; 70% (or &lt; 1.5 L) of predicted, or an exacerbation of asthma in the 6
             weeks preceding the study.

          8. An active infectious disease.

          9. Anemia that requires work-up, black stools, active bleeding.

         10. A history of gastrointestinal bleeding due to aspirin or other NSAIDS, gastritis, or
             duodenal ulcer not proven to be due to Helicobacter pylori.

         11. A history of hemophilia or any other bleeding disorder.

         12. Unstable angina.

         13. Participants taking aspirin and or other NSAIDs at the time of the study visits.

         14. Participants taking leukotriene receptors inhibitors or 5-lypooxygenase (5-LO)
             inhibitors at the time of the study visits.

         15. In addition, participants taking one or more of the following drugs intake last 14
             days prior to the enrollment will be excluded: lithium, warfarine, enoxaparin,
             heparin, dalteparin, fluconazole, ketotifen. Short-acting antihistamines should be
             stopped 5 days before the challenge; long-acting antihistamines should be stopped 1
             week prior to the challenge.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elina Jerschow, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Attending physician</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>The Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Jerschow E, Ren Z, Hudes G, Sanak M, Morales E, Schuster V, Spivack SD, Rosenstreich D. Utility of low-dose oral aspirin challenges for diagnosis of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol. 2016 Apr;116(4):321-328.e1. doi: 10.1016/j.anai.2015.12.026. Epub 2016 Jan 25.</citation>
    <PMID>26822279</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2011</study_first_submitted>
  <study_first_submitted_qc>March 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2011</study_first_posted>
  <results_first_submitted>January 8, 2016</results_first_submitted>
  <results_first_submitted_qc>April 3, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 5, 2016</results_first_posted>
  <last_update_submitted>September 26, 2017</last_update_submitted>
  <last_update_submitted_qc>September 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Montefiore Medical Center</investigator_affiliation>
    <investigator_full_name>Elina Jerschow</investigator_full_name>
    <investigator_title>Attending physician</investigator_title>
  </responsible_party>
  <keyword>aspirin</keyword>
  <keyword>asthma</keyword>
  <keyword>diagnosis</keyword>
  <keyword>prostaglandins</keyword>
  <keyword>leukotrienes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
    <mesh_term>Asthma, Aspirin-Induced</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>no, patients signed informed consent that allowed us to collect data for the present study but not to share the data</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Aspirin-sensitive Asthmatics</title>
          <description>Patients with aspirin exacerbated respiratory disease, N=16</description>
        </group>
        <group group_id="P2">
          <title>Aspirin-tolerant Asthmatics</title>
          <description>Aspirin tolerant asthma patients, N=13</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Aspirin-sensitive Asthmatics</title>
          <description>patients with aspirin exacerbated respiratory disease</description>
        </group>
        <group group_id="B2">
          <title>Aspirin-tolerant Asthmatics</title>
          <description>aspirin-tolerant patients with asthma</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.8" spread="3.2"/>
                    <measurement group_id="B2" value="42.6" spread="2.4"/>
                    <measurement group_id="B3" value="40.3" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Eicosanoid Metabolites Concentration</title>
        <description>eicosanoid metabolites concentration in plasma and urine 2 h post ASA challenge</description>
        <time_frame>2 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aspirin-sensitive Asthmatics</title>
            <description>Patients with aspirin exacerbated respiratory disease, N=16</description>
          </group>
          <group group_id="O2">
            <title>Aspirin-tolerant Asthmatics</title>
            <description>Aspirin tolerant asthma patients, N=13</description>
          </group>
        </group_list>
        <measure>
          <title>Eicosanoid Metabolites Concentration</title>
          <description>eicosanoid metabolites concentration in plasma and urine 2 h post ASA challenge</description>
          <units>log-pg/mg creatinine</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.91" spread="0.15"/>
                    <measurement group_id="O2" value="5.8" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment-Related Adverse Events</title>
        <description>Adverse reactions defined as bronchospasm requiring endotracheal intubation. The adverse reactions will be assessed through a post challenge follow-up with the patient at baseline and 24 hours after the challenge</description>
        <time_frame>24 hours after the challenge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aspirin-sensitive Asthmatics</title>
            <description>Patients with aspirin exacerbated respiratory disease, N=16</description>
          </group>
          <group group_id="O2">
            <title>Aspirin-tolerant Asthmatics</title>
            <description>Aspirin tolerant asthma patients, N=13</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment-Related Adverse Events</title>
          <description>Adverse reactions defined as bronchospasm requiring endotracheal intubation. The adverse reactions will be assessed through a post challenge follow-up with the patient at baseline and 24 hours after the challenge</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Forced Expiratory Volume in One Second (FEV1) in Aspirin Exacerbated Respiratory Disease (AERD) Patients</title>
        <description>We will assess FEV1% change from baseline at 12 months in AERD patients who have been on aspirin treatment for 12 months (current standard of care)</description>
        <time_frame>12 months</time_frame>
        <population>AERD patients will continue aspirin treatment for 12 months and the change from baseline in their FEV1% predicted will be monitored during this time</population>
        <group_list>
          <group group_id="O1">
            <title>Aspirin-sensitive Asthmatics</title>
            <description>Asthma patients with aspirin exacerbated respiratory disease</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Forced Expiratory Volume in One Second (FEV1) in Aspirin Exacerbated Respiratory Disease (AERD) Patients</title>
          <description>We will assess FEV1% change from baseline at 12 months in AERD patients who have been on aspirin treatment for 12 months (current standard of care)</description>
          <population>AERD patients will continue aspirin treatment for 12 months and the change from baseline in their FEV1% predicted will be monitored during this time</population>
          <units>change in percent predicted FEV1</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 hours</time_frame>
      <desc>patients will be assessed for adverse reactions during their aspirin challenge (standard of care)</desc>
      <group_list>
        <group group_id="E1">
          <title>Aspirin-sensitive Asthmatics</title>
          <description>Patients with aspirin exacerbated respiratory disease, N=16</description>
        </group>
        <group group_id="E2">
          <title>Aspirin-tolerant Asthmatics</title>
          <description>Aspirin tolerant asthma patients, N=13</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Elina Jerschow, attending physician</name_or_title>
      <organization>Montefiore Medical Center</organization>
      <phone>9173625291</phone>
      <email>ejerscho@montefiore.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

